Important Notice for PepGen Inc. Shareholders Regarding Lead Plaintiff Deadline in Ongoing Lawsuit

In a recent announcement, The Gross Law Firm has issued a crucial notice for shareholders of PepGen Inc., traded under the ticker symbol PEPG on NASDAQ. The firm advises all individuals who acquired shares of PepGen Inc. during the class period—spanning from March 7, 2024, to March 3, 2025—to consider contacting them for potential lead plaintiff appointment in a significant ongoing lawsuit.

Understanding the Lawsuit

The complaint purports that during the specified class period, the Defendants made materially false and/or misleading statements concerning PepGen Inc.'s lead product candidate, PGN-EDO51. Allegations suggest that the efficacy and safety of this candidate were overstated, ultimately deceiving investors. Over this timeframe, critical details were omitted about the drug's effectiveness and the risks associated with the CONNECT2 study, which is essential for U.S. FDA approval.

Key allegations include:
1. Misleading Efficacy Claims: It is claimed that PGN-EDO51 was not as effective or safe as the company had led investors to believe.
2. CONNECT2 Study Concerns: The CONNECT2 study was allegedly dangerous or flawed, raising concerns about the potential for the company's plans to secure market approval for PGN-EDO51.
3. Stalled Studies Predictions: The lawsuit asserts that PepGen may have to halt the CONNECT2 study, effectively jeopardizing the drug's clinical, regulatory, and commercial potential.
4. False Public Statements: The public claims made by the company's leadership are described as materially false and misleading.

The economic impacts of these allegations could be extensive for shareholders, prompting The Gross Law Firm to act on behalf of these investors. The firm operates on a mission to safeguard the interests of investors subjected to deceit and fraudulent actions.

Next Steps for Shareholders

PepGen Inc. shareholders are strongly urged not to miss the approaching deadline for registering as lead plaintiffs, set for August 8, 2025. Once registered, participants will gain access to a portfolio monitoring system, which will keep them informed regarding the lawsuit's progress throughout its lifecycle.

Importantly, registering as a lead plaintiff is not a prerequisite to participate in any recovery from the lawsuit, and shareholders can join the class action without incurring any financial obligation.

Why Engage the Gross Law Firm?

The Gross Law Firm is recognized nationally for their work in class action lawsuits, emphasizing the importance of ethical corporate behavior and accountability. They champion the rights of investors, particularly those adversely affected by misleading corporate practices. By working with a law firm of this caliber, shareholders can rest assured that their rights are being vigorously defended.

For shareholders who feel they might be impacted by this lawsuit, detailed registration links and contact information have been provided. It is advisable to act promptly and ensure participation in this critical judicial process.

For further inquiries and to register, shareholders can visit the Gross Law Firm's secure registration page.